Pfizer's Mid-Stage Tilrekimig Data Poses Threat to Regeneron's Dupixent, Shares Dip
REGN sits 63% above its 52-week low of $476.487.
Summary
Regeneron's stock is down approximately 1.2% in premarket trading following Pfizer's announcement of mid-stage data for tilrekimig, a potential competitor to Regeneron's blockbuster drug, Dupixent. Pfizer anticipates late-stage results in 2027-28. Separately, Regeneron has expanded its development portfolio by adding new programs in neurology and ophthalmology. While the pipeline expansion is a positive long-term strategic move, the immediate market reaction is driven by the competitive threat to Dupixent, a key revenue driver for Regeneron. This news introduces a new negative catalyst, contrasting with recent positive developments for Regeneron's other pipeline assets. Traders will closely watch Pfizer's progress with tilrekimig and any further details on Regeneron's new therapeutic programs.
At the time of this announcement, REGN was trading at $774.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.9B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.